Treatment of chronic hepatitis C in special groups

Journal of Hepatology, Supplement

Volumn 31, Issue 1, 1999, Pages 205-209

  Pol, Stanislas ^a   Zylberberg, Hervé ^a   Fontaine, Hélène ^a   Bréchot, Christian ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Chronic HCV; Hematologic disorder; Hepatitis C; HIV co infection; Renal disorders

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIRETROVIRUS AGENT; HEMOGLOBIN; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANEMIA; CLINICAL TRIAL; COMORBIDITY; CONFERENCE PAPER; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INHIBITION; HEMODIALYSIS PATIENT; HEMOGLOBINOPATHY; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IRON OVERLOAD; KIDNEY ALLOGRAFT; LIVER BIOPSY; LIVER CIRRHOSIS; PHOSPHORYLATION; PRIORITY JOURNAL;

EID: 0033407367     PISSN: 01695185     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0168-8278(99)80403-6     Document Type: Conference Paper

References (35)

1. Pereira BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995: 60: 799-805.
2. Zylberberg H, Pol S. Reciprocal interactions between human immunodeficiency virus and hepatitis C virus infections. Clin Infect Dis 1996: 23: 1117-1125.
3. Darby SC, Ewart DW, Giangrande PLF, Spooner RJD, Rizza CR, Dusheiko GM et al. for The UK Haemophilia Centre Directors' Organisation. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. Lancet 1997: 350: 1425-1431.
4. Ikura Y, Morimoto H, Johmura H, Kukui M, Sakurai M. Relationship between hepatic iron deposits and response to interferon in chronic hepatitis C. J Hepatol 1994: 91: 1367-1373.
5. Rumi MG, Santagostino E, Morfini M, Gringeri G, Tagariello G, Chistolini A et al. A multicenter controlled, randomized, open trial of interferon a-2b treatment of anti-human immunodeficiency virus-negative hémophilie patients with chronic hepatitis C. Blood 1997: 89: 3529-3533.
6. Makris M, Preston FE, Triger DR, Underwood JCE, Westlake L, Adelman MI. A randomized controlled trial of recombinant interferon-a in chronic hepatitis C in haemophiliacs. Blood 1991: 78: 1672-1677.
7. Peerlink K, Willems M, Sheng L, Nevens F, Fevery J, Yap SH et al. Rapid clearance of hepatitis C virus RNA in peripheral blood mononuclear cells of patients with clotting disorders and chronic hepatitis C treated with alpha-2b interferon is not a predictor for sustained response to treatment. BrJHaematol 1994:86:816-819.
8. Hanley JP, Jarvis LM, Andrews J, Dennis R, Hayes PC, Piris J et al. Interferon treatment for chronic hepatitis C infection in hemophiliacs. Influence of virus load, genotype and liver pathology on response. Blood 1996: 87: 1704-1709.
9. Di Marco V, Lo lacono O, Ciaccio C, Capra M, Rizzo M, Malizia R et al. Long-term efficacy of a- interferon in b-thalassemics with chronic hepatitis C. Blood 1997: 90: 2207-2212.
10. Yamada M, Fukuda Y, Nakano I, Katano Y, Takamatsu T, Hayakawa T. Serum hyaluronate as a marker of liver fibrosis in hemophiliacs with hepatitis C-associated chronic liver disease. Acta Haematol 1998: 99: 212-216.
11. Rodriguez-Inigo E, Tomas JF, Gomez-Garcia V, Bartolomé J, Pinilla I, Amaro MJ et al. Hepatitis C and G virus infection and liver dysfunction after allogeneic bone marrow transplantation: results from a prospective study. Blood 1997: 90: 1326-1331
12. Reichard O, Norkrans G, Frydén A, Braconier J-H, Sonnerborg A, Weiland O for the Swedish Study Group. A randomized double-blind, placebo-controlled trial of interferon-a2b with and without ribavirin for chronic hepatitis C. Lancet 1998: 351: 8387.
13. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C et al. A pilot study of combination with ribavirin plus interferon alpha for interferon alpha-resistant chronic hepatitis C. Gastroenterology 1994: 107: 812-817.
14. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G et al. Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998: 352: 1426-1432.
15. Me Hutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK et al. for The Hepatitis Interventional Therapy Group. Interferon alpha-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Ensl J Med 1998: 339: 1485-1492.
16. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon SC, Trcpo C et al. for The Hepatitis Interventional Therapy Group. Interferon alpha-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Enal J Med 1998: 339: 1493-1499.
17. Pol S, Thiers V, Carnot F, Zins B, Roméo R, Berthelot P et al. Efficacy and tolerance of a-2b Interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995: 47: 1412-1418.
18. Izopet J, Rostaing L, Moussion F, Alric L, Dubois M, That HT et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997: 176: 1614-1617.
19. Koenig P, Vogel W, Umlauft F, Weyrer K, Prommegger R, Lhotta K et al. Interferon treatment for chronic hepatitis C virus infection in urémie patients. Kidney Int 1994: 45: 1507-1509.
20. Raptopoulou-Gigi M, Spaia S, Garifallos A, Xenou P, Orphanou H, Zarafidou E et al. Interferon-a2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995: 10: 1834-1837.
21. Casanovas Taltavull T, Baliellas C, Sesé E, Iborra MJ, Benasco C et al. Interferon may be useful in hemodialysis patients with hepatitis C virus infection who are candidates for kidney transplant. Transplant Proc 1995: 27: 2229-2230.
22. Buisson C, Degos F, Daniel F, Dupuy A, Sari R, Simon N et al. Pharmacokinetics of interferon alpha-2b in haemodialysis (abstract). Nephrol Dial Transplant 1994: 9: 977-978.
23. Pol S, Thiers V, Nousbaum J-B, Legendre C, Berthelot P, Kreis H et al. The changing prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology 1995: 108: 581-583.
24. Thervet E , Pol S, Legendre C, Gagnadoux M-F, Cavalcanti R, Kreis H. Low-dose recombinant leukocyte interferon alpha treatment of hepatitis C viral infection in renal transplant recipients: a pilot study. Transplantation 1994: 58: 625-628.
25. Rostaing L, Izopet J, Baron E, Duffaut M, Puel J, Durand D. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995: 59: 1426-1431.
26. Gamier JJ, Chevallier P, Dubernard J-M, Trépo C, Touraine JL, Chossegros P. Treatment of hepatitis C virus infection with ribavirin in kidney transplant patients. Transpl Proc 1997: 29: 783-786.
27. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J et al. Pilot study of the combination of interferon alpha and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997: 26: 500-504.
28. Boyer N, Marcellin P-egolt C, Degos F, Saimot AG, Erlinger S et al. Recombinant interferon alpha for chronic hepatitis C in patients positive for antibody to human immunodeficiency virus. J Infect Dis 1992: 165: 723-726.
29. Marriott E, Navas S, Del Romero J, Garcia S, Castillo I, Quiroga JA et al. Treatment with recombinant alpha-interferon of chronic hepatitis C in anti-HIV positive patients. J Med Virol 1993: 40: 107-111.
30. Soriano V, Garcia-Samaniego J, Bravo R, Castro A, Odriozola PM, Gonzalez J. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV-infected patients. J Infection 1995:31:9-13.
31. Mauss S, Klinker H, Ulmer A, Willers R, Weibbrich B, Albrecht H et al. Response to treatment of chronic hepatitis C with interferon alpha in patients infected with HIV-1 is associated with higher CD4+ cell count. Infection 1998: 26: 20-23.
32. Vento S, Di Perri G, Cruciani M, Garofano T, Concia E, Basseti D. Rapid decline of CD4+ cells after alpha-interferon treatment in HIV-1 infection. Lancet 1993: 341: 1597.
33. Puoti M, Rossi S, Hammad I, Castelnuovo F, Spinetti A, Zaltron S et al. Effect of treatment with interferon alpha 2b on liver disease and survival in subjects with HIV and chronic viral active hepatitis [abstract no. 265]. Hepatoloay 1994: 20: 163 A.
34. Vogt MW, Hartson KL, Furman PA, Chou TC, Fyfe JA, Coleman LA et al. Ribavirin antagonizes the effect of azidothymidine on HIV replication. Science ~1987: 235: 1376-1379.
35. Zylbcrberg H, Benhamou Y, Landau A, Chaix M-L, Fontaine H, Bochet M et al. Short term ribavirin therapy does not influence HIV replication in HCV-HIV coinfccted subjects receiving AZT or D4T. Hepatology 1998: 28: 479 A (abstract).